الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 110 |  |  |
| | | from | 110 | | |
Abstract
Precision cancer treatment, known as immunotherapy, is on the rise. Cancer immunotherapy is likely safer than standard treatments like surgery, chemotherapy, and radiation since it is based on the individual patient’s genetic makeup.
Several immunotherapy medications, including immune checkpoint inhibitors anti-PD-1/PD-L1/CTLA-4 and CD19 CAR T, have been approved by the FDA for the treatment of different forms of cancer thanks to researchers’ dogged pursuit of this goal. The majority of cancer patients develop either primary or acquired resistance to currently available immunotherapy drugs, highlighting the need for innovative approaches.